The mission of the Survey Methods Core (SMC) facility is to assist Moffitt Cancer Center members with the design, implementation, and execution of research involving survey methods. Services provided by the SMC include consultations on research design, methods, and implementation, as well as the production and processing of scannable, web-based, and Computer Assisted Telephone Interviewing (CATI) surveys. Also offered are consultations about qualitative methods, including interviews, focus groups, and cognitive debriefing. The core has grown significantly since 2006. In addition to increasing and enhancing the range of services, the Core has added technical staff and expanded its physical space. The Core has more than doubled its space and now has four computer workstations in 300 square feet of space, as well as 300 square feet in a private CATI lab with four telephone interviewing stations. Currently there are three full-time positions and one part-time interviewer position. Since its inception, the SMC has implemented a working chargeback structure, increased its technical staff, and enhanced its menu of services. The Core's user base has been extended to include members from the Experimental Therapeutics and Molecular Oncology and Drug Discovery programs as well as those from the Health Outcomes and Behavior and Cancer Epidemiology. The Core requests CCSG Support of $83,457 which is 48% of its current operational budget. Over 84% of usage is by Moffitt members and peer-reviewed.
Survey methods are vital tools in cancer prevention, detection, and control research and are increasingly useful in clinical investigations of new cancer therapies. The data collection process, particularly for large-scale studies and studies using multiple sites, can be time consuming;however, services provided by the SMC have streamlined the process.
|Chung, Brile; Stuge, Tor B; Murad, John P et al. (2014) Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep 8:871-82|
|Charbonneau, Bridget; Block, Matthew S; Bamlet, William R et al. (2014) Risk of ovarian cancer and the NF-*B pathway: genetic association with IL1A and TNFSF10. Cancer Res 74:852-61|
|Unrod, Marina; Simmons, Vani N; Sutton, Steven K et al. (2014) A randomized clinical trial of self-help intervention for smoking cessation: research design, interventions, and baseline data. Contemp Clin Trials 38:284-90|
|Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256|
|Padron, Eric; Yoder, Sean; Kunigal, Sateesh et al. (2014) ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123:3675-7|
|Hampras, Shalaka S; Viscidi, Raphael P; Helzlsouer, Kathy J et al. (2014) Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23:2591-6|
|Chen, Ning; Chon, Hye Sook; Xiong, Yin et al. (2014) Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep 31:376-83|
|Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna et al. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1|
|Carvalho, Renato S; Fernandes, Vanessa C; Nepomuceno, Thales C et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15:840-50|
|Rizwani, Wasia; Schaal, Courtney; Kunigal, Sateesh et al. (2014) Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 9:e100888|
Showing the most recent 10 out of 108 publications